

Atty. Docket No.  
A32737 072396.0225

**Serial No.**  
**09/844,915**

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

O (Use several sheets if necessary)

**Applicant**  
**Robbins et al.**

Filing Date  
April 27, 2001

~~Group Art Unit~~  
1633 1635



## **U.S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENT**

**OTHER DOCUMENTS (including Author, Title Date, Pertinent Pages, Etc.)**

*6/29*

Ma et al., "Dual modifications, NF- $\kappa$ B deficiency and overexpression of IL-10, enhance DC tolerogenic activity," presented at American Transplant Congress 2003, May 30-June 4, Washington, DC.

*6/29*

Bonham et al., "Marked prolongation of cardiac allograft survival by dendritic cells genetically engineered with NF $\kappa$ B oligonucleotide decoys and adenoviral vectors encoding CTLA4-Ig<sup>1</sup>," Journal of Immunology, 2002, 169:3382-3391.

NY02:444373.1

1

**Examiner**

*Lena Bell*

### Date Considered

8/30/04

- \* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.